Information Library

Results for: Connect with investigators, regulators and physicians - Cost control/reduction - Late Phase

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • New FDA Guidance on Antidiabetic Therapies

    White Paper — December 11, 2009
    Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.

  • Early phase strategies

    Hear from the Experts — June 15, 2009
    Web cast about Early Phase Strategies.

  • Risk Assessment & Strategy

    Brochure — April 16, 2009
    Quintiles benefit risk analysis can help you anticipate potential regulatory concerns and highlight the benefit side of your drug’s benefit risk profile.

Page 1 of 1 (3 results)

Subscribe to Email Based on Your Interests

Set preferences